Cipla Limited
CIPLA
Κατάταξη σε μετοχές
#1810
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Τιμή μετοχής
$14.61
Τελευταίος συγχρονισμός: 2026-10-19
Κεφαλαιοποίηση
$11.81B
Αλλαγή (1 ημέρα)
-0.11%
Αλλαγή (1 έτος)
-21.65%
Χώρα
IN
Εμπόριο Cipla Limited (CIPLA)
Κατηγορία
Healthcare
Δείκτης P/S για Cipla Limited (CIPLA)
Δείκτης P/S στις October 2026 TTM: 3.82
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Cipla Limited, ο τρέχων δείκτης P/S (TTM) είναι 3.82. Στο τέλος του 2024, ο δείκτης ήταν 4.74.
Ιστορικό P/S για την Cipla Limited από 2004 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 3.82 | -10.80% |
| 2025 | 4.28 | -9.65% |
| 2024 | 4.74 | 47.08% |
| 2023 | 3.22 | -14.85% |
| 2022 | 3.78 | 10.05% |
| 2021 | 3.44 | 72.27% |
| 2020 | 2.00 | -23.06% |
| 2019 | 2.59 | -15.52% |
| 2018 | 3.07 | -7.69% |
| 2017 | 3.33 | 9.59% |
| 2016 | 3.03 | -39.81% |
| 2015 | 5.04 | 86.12% |
| 2014 | 2.71 | -27.40% |
| 2013 | 3.73 | 6.94% |
| 2012 | 3.49 | -98.05% |
| 2011 | 179.33 | 3,495.17% |
| 2010 | 4.99 | 44.67% |
| 2009 | 3.45 | -19.14% |
| 2008 | 4.26 | -20.21% |
| 2007 | 5.34 | -22.03% |
| 2006 | 6.85 | 94.90% |
| 2005 | 3.52 | -7.98% |
| 2004 | 3.82 | 0.00% |
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 84.88% |
IN
|
